TickerFacts.

Apimeds Pharmaceuticals US, Inc. (APUS): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$8.93M
Year ended 2025-12-31
-$13.28M
Trailing 12 months to 2026-06-30
2023-12-31: -$627.8K2024-12-31: -$733.5K2025-12-31: -$8.93M-$8.93M
2023-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$8.93Mn/m2026-05-04, From 2025-01-01
2024-12-31-$733.5Kn/m2026-05-04, From 2024-01-01
2023-12-31-$627.8Kn/a2025-04-15, From 2023-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Apimeds Pharmaceuticals US, Inc. (APUS)2025-12-31-$8.93Mn/m
Cypherpunk Technologies Inc. (CYPH)2025-12-31-$43.90Mn/m
Transcode Therapeutics, Inc. (RNAZ)2025-12-31-$19.52Mn/m
Gyre Therapeutics, Inc. (GYRE)2025-12-31$1.01Mn/m
Climb Bio, Inc. (CLYM)2025-12-31-$54.36Mn/m
Aclaris Therapeutics, Inc. (ACRS)2025-12-31-$47.11Mn/m
Aquestive Therapeutics, Inc. (AQST)2025-12-31-$52.43Mn/m
Corbus Pharmaceuticals Holdings, Inc. (CRBP)2025-12-31-$64.49Mn/m
Eledon Pharmaceuticals, Inc. (ELDN)2025-12-31-$62.34Mn/m

Compare APUS, CYPH, RNAZ, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗